Lane, A., Luskin, M., Keating, J., Leboeuf, N., Garcia, J., Shimony, S., Leonard, R., Goodpaster, A., Nguyen, T., Galinsky, I., Eberly-Puleo, A., Daver, N., Jain, N., Garcia-Manero, G., Kantarjian, H., Konopleva, M., Stein, A. S., Pemmaraju, N. (2025). Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial. Blood. https://doi.org/10.1182/blood-2025-653